The inhibition of PCSK9, therefore, acts to attenuate PCSK9‐led LDLR degradation, increase lipid clearance and lower serum LDL‐C.7 Since hyperlipidemia has been shown to aggravate myocardial ischaemia‐reperfusion (I/R) injury and attenuate the cardioprotective effects of pre‐conditioning, a lipid‐lowering drug might mitigate I/R injury.8 This evidence concerns the gene PCSK9 and hyperlipidemia.